Individuals in Canada who are currently receiving or have previously received belantamab mafodotin for multiple myeloma (MM) may be eligible to participate in a research interview study. This study aims to better understand patients’ experiences with belantamab...

We are pleased to share that the study Real-World Outcomes in Myeloma Patients With t(11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database has been published in Clinical Lymphoma Myeloma & Leukemia. Congratulations to...

We are delighted to announce that a poster on Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma was presented at the International Myeloma Society (IMS) meeting and subsequently published in Clinical...